Jefferies Starts Abbvie (ABBV) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/4/2026
- S&P 500, Dow hit record highs on strong AI-linked earnings, Mideast deal hopes
- Caterpillar stock jumps on strong earnings and revenue beat
- Optical component stocks rally on proposed U.S. ban on Chinese tech
- BofA says this memory stock could double. Here are 5 reasons why
- Merck shares rise on big Q2 earnings beat, adjusted FY outlook
- Palantir posts 93% revenue growth in Q2 2026, raises full-year outlook
- Nutanix to cut 5% of workforce, expects up to $43M in charges
- Grainger CFO resigns, interim replacement named
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Walmart dips after Oppenheimer downgrades shares on difficult short-term setup
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
Wells Fargo Starts Abbvie (ABBV) at Outperform
January 16, 2013 8:15 AM ESTWells Fargo initiates coverage on Abbvie (NYSE: ABBV) with a Outperform rating and $37-$40 valuation range.
The firm is confident in the near-term growth prospects of Humira and AndroGel, and likes the long-term potential of ABBV's all-oral HCV regimen and elotuzumab. The firm also views... More
